Literature DB >> 16199895

Galectin-3 Expression in Functioning and Silent ACTH-Producing Adenomas.

Long Jin1, Dominik Riss, Katharina Ruebel, Sabine Kajita, Bernd W Scheithauer, Eva Horvath, Kalman Kovacs, Ricardo V Lloyd.   

Abstract

Galectin-3 (Gal-3), a beta galactoside-binding protein, has been implicated in a variety of biological functions including cell growth, differentiation, tumor cell adhesion, angiogenesis, tumor progression, and metastasis. We recently reported that Gal-3 was expressed in a subset of normal pituitary cells and tumors including PRL, ACTH, and in folliculo-stellate (FS) cells and tumors and that Gal-3 had an important regulatory role in pituitary cell proliferation. We further investigated the expression of Gal-3 protein in ACTH- and PRL-producing tumors and the expression of various galectin mRNAs by RT-PCR in pituitary adenomas and normal pituitary. Most silent ACTH subtypes 1 and 2 adenomas were negative or only focally positive for Gal-3 expression compared to functioning ACTH tumors from patients with Cushing's disease and Nelson's syndrome. In the normal pituitary, Gal-3 was expressed in less than 1% of the basophil-invading cells (ACTH cells present in the posterior pituitary) and in a subset of the anterior lobe ACTH-positive cells. RT-PCR analyses showed that many members of the galectin family including galectins 1, 2, 3, 4, 5, 6, 7, 8, and 9 were expressed in normal pituitary and in functioning ACTH- and PRL-producing tumors. These results indicate that Gal-3 is associated with functioning ACTH and PRL tumors and is expressed infrequently in silent ACTH adenomas, suggesting that Gal-3 protein and/or gene is altered in non-functioning ACTH tumors. The use of ACTH and Gal-3 immunostaining should help in the diagnosis of silent ACTH adenomas.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16199895     DOI: 10.1385/ep:16:2:107

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  39 in total

1.  Galectin-3 expression is induced in cirrhotic liver and hepatocellular carcinoma.

Authors:  D K Hsu; C A Dowling; K C Jeng; J T Chen; R Y Yang; F T Liu
Journal:  Int J Cancer       Date:  1999-05-17       Impact factor: 7.396

2.  Analysis of homogeneous populations of anterior pituitary folliculostellate cells by laser capture microdissection and reverse transcription-polymerase chain reaction.

Authors:  L Jin; I Tsumanuma; K H Ruebel; J M Bayliss; R V Lloyd
Journal:  Endocrinology       Date:  2001-05       Impact factor: 4.736

3.  Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures.

Authors:  H Lahm; S André; A Hoeflich; J R Fischer; B Sordat; H Kaltner; E Wolf; H J Gabius
Journal:  J Cancer Res Clin Oncol       Date:  2001       Impact factor: 4.553

Review 4.  Beta-1,4-galactosylation of N-glycans is a complex process.

Authors:  K Furukawa; T Sato
Journal:  Biochim Biophys Acta       Date:  1999-12-06

5.  Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest.

Authors:  Tadashi Yoshii; Tomoharu Fukumori; Yuichiro Honjo; Hidenori Inohara; Hyeong-Reh Choi Kim; Avraham Raz
Journal:  J Biol Chem       Date:  2001-11-27       Impact factor: 5.157

6.  Analysis of endocrine active and clinically silent corticotropic adenomas by in situ hybridization.

Authors:  R V Lloyd; K Fields; L Jin; E Horvath; K Kovacs
Journal:  Am J Pathol       Date:  1990-08       Impact factor: 4.307

Review 7.  Ultrastructural diagnosis of human pituitary adenomas.

Authors:  E Horvath; K Kovacs
Journal:  Microsc Res Tech       Date:  1992-01-15       Impact factor: 2.769

Review 8.  Ultrastructural markers in the pathologic diagnosis of pituitary adenomas.

Authors:  E Horvath
Journal:  Ultrastruct Pathol       Date:  1994 Jan-Apr       Impact factor: 1.094

9.  Galectin-3 is a novel substrate for human matrix metalloproteinases-2 and -9.

Authors:  J Ochieng; R Fridman; P Nangia-Makker; D E Kleiner; L A Liotta; W G Stetler-Stevenson; A Raz
Journal:  Biochemistry       Date:  1994-11-29       Impact factor: 3.162

10.  Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications.

Authors:  X C Xu; A K el-Naggar; R Lotan
Journal:  Am J Pathol       Date:  1995-09       Impact factor: 4.307

View more
  13 in total

Review 1.  MicroRNAs in the human pituitary.

Authors:  Milani Sivapragasam; Fabio Rotondo; Ricardo V Lloyd; Bernd W Scheithauer; Michael Cusimano; Luis V Syro; Kalman Kovacs
Journal:  Endocr Pathol       Date:  2011-09       Impact factor: 3.943

Review 2.  Predictors of silent corticotroph adenoma recurrence; a large retrospective single center study and systematic literature review.

Authors:  Fabienne Langlois; Dawn Shao Ting Lim; Chris G Yedinak; Isabelle Cetas; Shirley McCartney; Justin Cetas; Aclan Dogan; Maria Fleseriu
Journal:  Pituitary       Date:  2018-02       Impact factor: 4.107

Review 3.  Silent corticotroph adenomas.

Authors:  Odelia Cooper
Journal:  Pituitary       Date:  2015-04       Impact factor: 4.107

4.  MicroRNA expression in ACTH-producing pituitary tumors: up-regulation of microRNA-122 and -493 in pituitary carcinomas.

Authors:  Gail Stilling; Zhifu Sun; Shuya Zhang; Long Jin; Alberto Righi; Gábor Kovācs; Márta Korbonits; Bernd W Scheithauer; Kalman Kovacs; Ricardo V Lloyd
Journal:  Endocrine       Date:  2010-05-27       Impact factor: 3.633

Review 5.  Modification of hormonal secretion in clinically silent pituitary adenomas.

Authors:  Tania Daems; Johan Verhelst; Alex Michotte; Pascale Abrams; Dirk De Ridder; Roger Abs
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

6.  Expression of galectin-3 correlates with apoptosis in pituitary adenoma cells.

Authors:  Chui-Xue Huang; Yong-Hong Hou; Yun-Sheng Liu
Journal:  Neurosci Bull       Date:  2008-02       Impact factor: 5.203

Review 7.  Immunohistochemical Biomarkers in Thyroid Pathology.

Authors:  Zubair Baloch; Ozgur Mete; Sylvia L Asa
Journal:  Endocr Pathol       Date:  2018-06       Impact factor: 3.943

Review 8.  High-risk pituitary adenomas and strategies for predicting response to treatment.

Authors:  George Kontogeorgos; Eleni Thodou; Robert Y Osamura; Ricardo V Lloyd
Journal:  Hormones (Athens)       Date:  2022-01-21       Impact factor: 2.885

9.  Gene expression profiling in human corticotroph tumours reveals distinct, neuroendocrine profiles.

Authors:  Maria Francesca Cassarino; Alberto G Ambrogio; Andrea Cassarino; Maria Rosa Terreni; Davide Gentilini; Antonella Sesta; Francesco Cavagnini; Marco Losa; Francesca Pecori Giraldi
Journal:  J Neuroendocrinol       Date:  2018-08-07       Impact factor: 3.627

Review 10.  Galectin-3-Mediated Glial Crosstalk Drives Oligodendrocyte Differentiation and (Re)myelination.

Authors:  Laura Thomas; Laura Andrea Pasquini
Journal:  Front Cell Neurosci       Date:  2018-09-12       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.